Cancer metastasis

March 3, 2019

Combinatorial therapy for attenuating prostate cancer bone metastasis: A pharmaceutical mixture encompassing  Simvastatin and Navitoclax (SAN) inhibits the expression of Monoamine oxidase A (MAOA), inhibits Shh-IL6-RANKL signaling network, suppresses tumor-stromal interactions, reduces prostate cancer metastasis and prolongs survival via upregulation of its target gene, 3/March/2019, 8.33 am

Introduction: What they say: A study from the Uro-Oncology Research Program, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA shows that “MAOA-Dependent Activation of […]
February 24, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Canthardin   and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 25/February/2019, `1.27 am

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells […]
February 19, 2019

Combinatorial therapy for metastasis: A pharmacological mixture Simvastatin and Navitoclax/ABT-263 (SAN) inhibits the expression of IL-6/8, decreases the expression of downstream molecules WASF3 and Arp2/3, suppresses tumor cell migration, reduces metastasis and prolongs survival via up regulation of its target gene, 20/February/2019, 12.54 am

Introduction: What they say: A study from Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, Maryland 21218, USA; Johns Hopkins Physical Sciences-Oncology Center, The Johns […]
February 19, 2019

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing  Fenofibrate and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 19/February/2019, `3.13 pm

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem […]